A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines

Allergan33 enrolled

Overview

This study will evaluate the effectiveness and benefit of treatment with onabotulinumtoxinA in Chronic Migraine patients who have received a minimum of 7 treatment cycles.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Chronic Migraine, Headaches

Interventions

onabotulinumtoxinABIOLOGICAL

Previous treatment with onabotulinumtoxinA for Chronic Migraine.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 15 or more headache days over a 30 day period * A minimum of 7 treatment cycles with onabotulinumtoxinA Exclusion Criteria: * Any treatment cycle dose of onabotulinumtoxinA greater than 200 units

Locations (1)

Unnamed facility

Encinitas, California, United States

Outcomes

Primary Outcomes

Change From Baseline in the Number of Headache Days

The mean number of headache days was counted as the number of headache days occurring during the 30 day period ending with treatment cycle 7. Each treatment cycle was administered approximately every 12 weeks.

Time frame: Treatment Cycle 7 (approximately 1.5 years)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.